Novo Nordisk Aims for U.S. Approval for Tresiba
Jan. 31 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk A/S stuck to its target of getting U.S. approval for the diabetes treatment Tresiba in the first half as it’s counting on the product to reach higher 2013 forecasts. She speaks on Bloomberg Television's "The Pulse."
Most Recent Videos
Cultivating Top Crops With a Drone’s Watchful Eye
19:06 - Agriculture is one of humanity's oldest and biggest businesses. The World Bank estimates the industry is worth more than $2.4 trillion. But as land grows scarcer and climate patterns more unruly, new technologies will be needed to squeeze the most out of our production. In an interview with Bloomberg North’s Anthony Lacavera, Max Bruner, CEO and co-founder of San Francisco-based company Mavrx, explains how they’re giving farmers what even the most powerful satellites can't: a clear eye on their crops, no matter the conditions. (Source: Bloomberg)